EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic Urothelial Carcinoma

Takahiro Harano, Masaomi Ikeda, Shuhei Hirano, Soichiro Shimura, Masayoshi Toyoda, Satoshi Okuda, Dai Koguchi, Hideyasu Tsumura, Daisuke Ishii, Kazumasa Matsumoto

Chemotherapy · 2024

DOI: 10.1159/000543333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, 2024. Verfasst von Takahiro Harano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan, turbo.1229@gmail.com. Hauptthemen laut MEDLINE: Filgrastim, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms, Urologic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) therapy is indicated as first-line or neoadjuvant chemotherapy (NAC) for patients with advanced or metastatic urothelial carcinoma (UC). However, no studies reported ddMVAC therapy with pegfilgrastim (3.6 mg) in Japanese patients. We investigated the safety and efficacy of ddMVAC therapy with pegfilgrastim in patients with advanced or metastatic UC.

Methods

A total of 43 patients received ddMVAC therapy with pegfilgrastim (3.6 mg) from February 2021 to December 2023. Among them, 25 and 18 patients received this regimen as first-line chemotherapy and NAC, respectively. We assessed toxicity and efficacy using Common Terminology Criteria for Adverse Events version 4.0 and Response Evaluation Criteria in Solid Tumors version 1.1, respectively.

Results

The median number of ddMVAC therapy cycles was 3 (range: 1–5), with a total of 131 cycles. Cisplatin at the full dose without reduction was administered to 24 (56%) patients. Grade ≥3 hematologic toxicity occurred in 15 (35%) patients. Among them, anemia, neutropenia, thrombocytopenia, and febrile neutropenia were 13.9%, 9.3%, 11.7%, and 7.0%, respectively. Regarding non-hematologic toxicity, grade 3 appetite loss was observed in 2 (5%) patients. Complete response was observed in 7 (16%) patients and partial response in 26 patients (60%), yielding an objective response rate of 76%. Pathologic complete response (pCR; ypT0pN0) was observed in 3 (16.7%) patients and downstaging occurred in 13 (72.2%) patients. The median progression-free survival and overall survival of first-line treatment with ddMVAC were 18.6 months and not reached, respectively.

Conclusion

The ddMVAC with pegfilgrastim (3.6 mg) reduced injection-related patient burden, caused fewer grade ≥3 adverse events, and demonstrated similar efficacy when compared to the original ddMVAC regimen that used granulocyte colony-stimulating factor for 7 consecutive days.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FilgrastimAntineoplastic Combined Chemotherapy ProtocolsUrinary Bladder NeoplasmsUrologic NeoplasmsHumansCisplatinMaleFemaleAgedMiddle AgedMethotrexatePolyethylene GlycolsDoxorubicinVinblastineJapanEast Asian People

Stichwörter der Autor:innen

Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatinNeoadjuvant chemotherapyPegfilgrastimSafety · First-line treatment

Substanzen

FilgrastimpegfilgrastimCisplatinMethotrexatePolyethylene GlycolsDoxorubicinVinblastine

Autor:innen und Institutionen

  • Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan, turbo.1229@gmail.com.
  • Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan.

Zitieren

APA

Harano, T., Ikeda, M., Hirano, S., Shimura, S., Toyoda, M., Okuda, S., Koguchi, D., Tsumura, H., Ishii, D., & Matsumoto, K. (2024). Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic Urothelial Carcinoma. Chemotherapy. https://doi.org/10.1159/000543333

Vancouver

Harano T, Ikeda M, Hirano S, Shimura S, Toyoda M, Okuda S, et al. Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic Urothelial Carcinoma. Chemotherapy. 2024. doi:10.1159/000543333

BibTeX
@article{Harano2024,
  author = {Harano, Takahiro and Ikeda, Masaomi and Hirano, Shuhei and Shimura, Soichiro and Toyoda, Masayoshi and Okuda, Satoshi and Koguchi, Dai and Tsumura, Hideyasu and Ishii, Daisuke and Matsumoto, Kazumasa},
  title = {Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic Urothelial Carcinoma},
  journal = {Chemotherapy},
  year = {2024},
  doi = {10.1159/000543333}
}
Kostenlos starten →